May 27 (Reuters) - Tvardi Therapeutics Inc TVRD.O:
TVARDI THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TTI-101 IN IDIOPATHIC PULMONARY FIBROSIS
TVARDI THERAPEUTICS INC - TOPLINE DATA FROM REVERT IPF TRIAL EXPECTED IN Q4 2025
Source text: ID:nBw4830W3a
Further company coverage: TVRD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.